null

BioSim™ anti-Infliximab (Remicade®) (Human) ELISA Kit

(No reviews yet) Write a Review
SKU:
26-E4387
Availability:
Usually Shipped in 5 Working Days
Size:
100 Assays
Storage Conditions:
4°C
Shipping Conditions:
Gel Pack
Shelf life:
12 months
€1,453.00
Frequently bought together:

Description

Infliximab (Remicade®) is a therapeutic chimeric monoclonal antibody against tumor necrosis factor (TNF) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Infliximab drug inhibits the action of TNF and reduces the inflammation and subsequently improves the patient’s health. Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Infliximab ELISA kit is designed to quantify/measure the antibody against Infliximab with high specificity and sensitivity in biological matrices.

Alternate Name: N/A

Tag Line: A Sandwich ELISA kit for the quantitative measurement of antibody against Infliximab in human serum or plasma.

Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- quantitative measurement of antibody against Infliximab in human serum and plasma

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: This ELISA kit is used for quantitative measurement of antibody against Infliximab in human serum and plasma

Features & Benefits: Easy, convenient, sensitive and time-saving method to measure the level of antibody against Infliximab in human serum and plasma. Detection Range: 62 - 500 ng/ml Sensitivity: 15 ng/ml Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100) Cross Reactivity: Infliximab (Remicade®) infusion camouflages/masks the presence of antibody to infliximab (ATI) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATI. It is convenient to obtain blood sample just before the infusion of infliximab or at least 2 weeks after the infusion of infliximab. Recovery rate: 85 – 115% with normal human serum samples with known concentrations

View AllClose